Mainz Biomed BV (MYNZ) - Total Liabilities
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has total liabilities worth $4.69 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mainz Biomed BV - Total Liabilities Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's total liabilities have evolved over time, based on quarterly financial data. See Mainz Biomed BV short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Mainz Biomed BV Competitors by Total Liabilities
The table below lists competitors of Mainz Biomed BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
Indonesia | Rp326.94 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Viking Mines Ltd
AU:VKA
|
Australia | AU$370.98K |
|
First Media Tbk
JK:KBLV
|
Indonesia | Rp1.44 Trillion |
|
Thai Coating Industrial Public Company Limited
BK:TCOAT
|
Thailand | ฿100.61 Million |
|
Pryme BV
OL:PRYME
|
Norway | Nkr20.61 Million |
|
ECOUP OYJ EO 1
F:62H
|
Germany | €12.21 Million |
|
SWS Capital Bhd
KLSE:7186
|
Malaysia | RM38.01 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Mainz Biomed BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MYNZ stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mainz Biomed BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mainz Biomed BV (2019–2025)
The table below shows the annual total liabilities of Mainz Biomed BV from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.69 Million | -34.84% |
| 2024-12-31 | $7.19 Million | -40.86% |
| 2023-12-31 | $12.16 Million | +97.88% |
| 2022-12-31 | $6.14 Million | +67.00% |
| 2021-12-31 | $3.68 Million | +7.75% |
| 2020-12-31 | $3.41 Million | +28.08% |
| 2019-12-31 | $2.67 Million | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more